The contribution of the CysLT1 signaling pathway in the clinical manifestations of asthma is supported by the finding that, in addition to the 5-LO inhibitor zileuton [51], CysLT receptor antagonists or leukotriene receptor antagonists (LTRAs) montelukast, zafirlukast, and pranlukast are effective treatments [37,83]. Here, CYSLTR1 is linked to asthma.